Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

This study is currently recruiting participants.
Verified January 2014 by Kyowa Hakko Kirin Pharma, Inc.
Sponsor:
Collaborator:
Teva Pharma
Information provided by (Responsible Party):
Kyowa Hakko Kirin Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01447732
First received: September 30, 2011
Last updated: January 22, 2014
Last verified: January 2014

September 30, 2011
January 22, 2014
October 2011
June 2014   (final data collection date for primary outcome measure)
Adverse Event collection and assessment will be done for all 74 potentially treated subjects. [ Time Frame: at least 30 days or up to 12 weeks ] [ Designated as safety issue: Yes ]
The safety of CEP-37250/KHK2804 will be determined by reported adverse events (AEs), changes in the physical examinations, vital laboratory evaluations, and treatment discontinuations due to toxicity.
Same as current
Complete list of historical versions of study NCT01447732 on ClinicalTrials.gov Archive Site
  • To assess PK parameters which include: area under the plasma concentration versus time curve (AUC), peak plasma concentration (Cmax), t 1/2 and CL of CEP-37250/KHK2804. [ Time Frame: at least 30 days or up to 12 weeks ] [ Designated as safety issue: No ]
    Participating subjects will have serial blood samples taken to determine the PK profile of study drug.
  • To screen for the development of antibodies against CEP-37250/KHK2804 (immunogenicity) [ Time Frame: at least 30 days or up to 12 weeks ] [ Designated as safety issue: Yes ]
    Subjects will have serial blood samples to check for the developments of anti-CEP-37250/KHK2804 antibodies.
  • To evaluate preliminary efficacy (overall response (Objective response rate(ORR; Complete Response(CR)+Partial Response(PR) and clinical benefit rate(CR+PR+stable disease(SD)). [ Time Frame: up to 30 days or up to 12 weeks ] [ Designated as safety issue: Yes ]
    Tumor measurements and disease response assessments will be performed on all participating subjects.
Same as current
Not Provided
Not Provided
 
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

This is a two-part, Phase 1 open label, multi-center, dose escalation study of CEP-37250/KHK2804 as monotherapy in subjects with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.

The study will be conducted in two parts. In Part 1, a standard 3+3 designed dose escalation phase, subjects will receive CEP-37250/KHK2804, administered iv, once every week. A treatment cycle will consists of total of four doses per cycle. Part 2 of the study will enroll subjects with either colon cancer or pancreatic cancer to receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.

All subjects will receive study therapy until disease progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the subject, or Investigator decision, up to a maximum of six cycles (approximately six months). After six cycles of CEP-37250/KHK2804 therapy, the subject may continue to receive CEP-37250/KHK2804 after discussion with the Sponsor and determination that the subject is experiencing a best response of at least stable disease (SD) and is not experiencing any unacceptable toxicities or dose limiting toxicities (DLTs).

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Solid Tumour
  • Adenocarcinoma of the Colorectal
  • Adenocarcinoma of the Pancreas
Drug: CEP-37250/KHK2804

Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight.

Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.

Other Name: KHK2804
  • Experimental: Part 1
    Dose escalation in subjects with advanced solid tumors
    Intervention: Drug: CEP-37250/KHK2804
  • Experimental: Part 2
    Subjects with colorectal or pancreatic cancer
    Intervention: Drug: CEP-37250/KHK2804
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
74
August 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adequate hepatic, renal, and hematologic function;
  • Life expectancy > 3 months;
  • Part 1 and 2: The subject has histopathologically or cytologically documented, measurable, unresectable, locally advanced primary or recurrent, metastatic solid tumor, locally advanced primary or recurrent, metastatic pancreatic adenocarcinoma and must have received at least one prior treatment regimen containing gemcitabine or 5-FU, and locally advanced primary or recurrent, metastatic colon adenocarcinoma.

Exclusion Criteria:

  • Parts 1 and 2:

    1. Malignant melanoma, Merkel cell cancer, small cell lung cancer, lymphoepithelial carcinoma, malignant mesothelioma, GIST, Hodgkin and NHL, thymoma, neuroendocrine, neuronal tumors, and sarcomas. This list of excluded tumors may be modified as additional research findings become available on target antigen expression;
    2. The subject has received anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks (6 weeks for mitomycin C and nitrosoureas) prior to the first dose of CEP-37250/KHK2804;
    3. The subject has received monoclonal antibodies of any type or for any form of disease within 4 weeks of the first dose of CEP-37250/KHK2804;
    4. Major surgery within 4 weeks prior to the first dose;
    5. Known symptomatic brain metastases (screening magnetic resonance imaging (MRI) of the brain is only required when there is clinical suspicion of central nervous system [CNS] involvement or past history of treated brain metastasis). Subjects with treated brain metastasis (radiotherapy and/or surgery) will be eligible if they:
  • Have completed treatment for their brain metastasis > 4 weeks prior to scheduled study treatment start date;
  • Are neurologically stable;
  • Are on corticosteroids in doses no greater than physiological replacement (e.g., dexamethasone < 1.5 mg/day); and
  • Have a screening MRI scan of the brain that specifically verifies no evidence of CNS hemorrhage and no active gadolinium enhancing lesions;
  • Subjects with primary brain/CNS malignancy (e.g., gliomas, lymphomas) are excluded.

    • Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or allergy to any component of the CEP-37250/KHK2804 finished drug and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-HT3 antagonists, or corticosteroids.
Both
18 Years and older
No
Contact: Mei M Hentrup, BSN, BS 609.580.7414 mhentrup@kyowa-kirin-pharma.com
Contact: Vincent Strout, MBA 609.919.1100 vstrout@kyowa-kirin-pharma.com
United States
 
NCT01447732
CEP-37250/KHK2804-001
No
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Hakko Kirin Pharma, Inc.
Teva Pharma
Study Director: Michael Tirgan, MD Kyowa Hakko Kirin Pharma, Inc.
Kyowa Hakko Kirin Pharma, Inc.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP